BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 21078806)

  • 1. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.
    Ziebell M; Holm-Hansen S; Thomsen G; Wagner A; Jensen P; Pinborg LH; Knudsen GM
    J Nucl Med; 2010 Dec; 51(12):1885-91. PubMed ID: 21078806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.
    Ziebell M
    Dan Med Bull; 2011 May; 58(5):B4279. PubMed ID: 21535991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.
    Booij J; de Jong J; de Bruin K; Knol R; de Win MM; van Eck-Smit BL
    J Nucl Med; 2007 Mar; 48(3):359-66. PubMed ID: 17332612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Extrastriatal
    Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J
    J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
    [No Abstract]   [Full Text] [Related]  

  • 7. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion.
    Pinborg LH; Ziebell M; Frøkjaer VG; de Nijs R; Svarer C; Haugbøl S; Yndgaard S; Knudsen GM
    J Nucl Med; 2005 Jul; 46(7):1119-27. PubMed ID: 16000280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Test-retest reproducibility of extrastriatal binding with
    Matsuoka K; Yasuno F; Shinkai T; Miyasaka T; Takahashi M; Kiuchi K; Kosaka J; Inoue M; Kichikawa K; Hasegawa M; Kishimoto T
    Psychiatry Res Neuroimaging; 2016 Dec; 258():10-15. PubMed ID: 27814458
    [No Abstract]   [Full Text] [Related]  

  • 9. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
    Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
    Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects.
    Koopman KE; la Fleur SE; Fliers E; Serlie MJ; Booij J
    J Nucl Med; 2012 Jul; 53(7):1087-90. PubMed ID: 22627000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.
    Goodman MM; Chen P; Plisson C; Martarello L; Galt J; Votaw JR; Kilts CD; Malveaux G; Camp VM; Shi B; Ely TD; Howell L; McConathy J; Nemeroff CB
    J Med Chem; 2003 Mar; 46(6):925-35. PubMed ID: 12620070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.
    Koch W; Unterrainer M; Xiong G; Bartenstein P; Diemling M; Varrone A; Dickson JC; Tossici-Bolt L; Sera T; Asenbaum S; Booij J; Kapucu OL; Kluge A; Ziebell M; Darcourt J; Nobili F; Pagani M; Hesse S; Vander Borght T; Van Laere K; Tatsch K; la Fougère C
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1938-46. PubMed ID: 24806112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study.
    Shang Y; Gibbs MA; Marek GJ; Stiger T; Burstein AH; Marek K; Seibyl JP; Rogers JF
    J Clin Psychopharmacol; 2007 Feb; 27(1):71-5. PubMed ID: 17224717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT.
    Abi-Dargham A; Gandelman MS; DeErausquin GA; Zea-Ponce Y; Zoghbi SS; Baldwin RM; Laruelle M; Charney DS; Hoffer PB; Neumeyer JL; Innis RB
    J Nucl Med; 1996 Jul; 37(7):1129-33. PubMed ID: 8965183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys.
    Booij J; Andringa G; Rijks LJ; Vermeulen RJ; De Bruin K; Boer GJ; Janssen AG; Van Royen EA
    Synapse; 1997 Nov; 27(3):183-90. PubMed ID: 9329154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain.
    Kuikka JT; Akerman K; Bergström KA; Karhu J; Hiltunen J; Haukka J; Heikkinen J; Tiihonen J; Wang S; Neumeyer JL
    Eur J Nucl Med; 1995 Jul; 22(7):682-6. PubMed ID: 7498231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute administration of haloperidol does not influence 123I-FP-CIT binding to the dopamine transporter.
    Booij J; van Loon G; de Bruin K; Voorn P
    J Nucl Med; 2014 Apr; 55(4):647-9. PubMed ID: 24604911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An
    van der Zande JJ; Joling M; Happach IG; Vriend C; Scheltens P; Booij J; Lemstra AW
    Neuroimage Clin; 2020; 25():102062. PubMed ID: 31790878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter.
    Emond P; Garreau L; Chalon S; Boazi M; Caillet M; Bricard J; Frangin Y; Mauclaire L; Besnard JC; Guilloteau D
    J Med Chem; 1997 Apr; 40(9):1366-72. PubMed ID: 9135033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.
    Koch W; Radau PE; Hamann C; Tatsch K
    J Nucl Med; 2005 Jul; 46(7):1109-18. PubMed ID: 16000279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.